// App-Quantinova.ai

409.0 : A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (MOBILITY-002 Trial, NCT02428270).

Researchers

Presenter

  • Kyaw Lwin Aung

Principal Investigators

  • Elaine McWhirter

  • Stephen Welch

  • Lisa Wang

  • Sophia Lovell

  • Lee-Anne Stayner

  • Saara Ali

  • Anne Malpage

  • Barbara Makepeace

  • Makilpriya Ramachandran

  • Neesha C. Dhani

  • David W. Hedley

  • Jennifer J. Knox

  • Lillian L. Siu

  • Rachel Anne Goodwin

  • Philippe L. Bedard

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada

  • London Regional Cancer Centre, London, ON, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • The Ottawa Hospital, Ottawa, ON, Canada

  • London Health Sciences Center, London, ON, Canada

  • Juravinski Cancer Centre, Burlington, ON, Canada

  • National Cancer Institute of Canada Clinical Trials Group, The Ottawa Hospital, Ottawa, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • GSK2256098

  • Trametinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02428270

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved